Google+ Facebook Twitter Twitter

Brain cancer liquid biopsy

Early detection of brain cancer has moved one step closer, according to new research.

New testing technology – the Dxcover Liquid Biopsy – has been shown to be effective even in the earlier days of cancer growth, at a smaller volume and lower stage.

Matt Baker, one of the scientists behind the test, said: “This breakthrough is a watershed moment in the development of early cancer detection. The study demonstrates the effectiveness of our Dxcover Brain Cancer Liquid Biopsy at detecting even the smallest brain tumours, which is great news for the care of future brain cancer patients.”

The study involved 177 patients with varying sizes of brain tumours providing blood samples for analysis by Dxcover.

The samples underwent the spectroscopic analysis under infra-red light and were processed using machine learning software. The test and analysis were found to be effective in identifying brain tumours in patients with gliomas as small as 0.2 cm3.

Dxcover Limited has raised £5.1m in funding to develop its spectroscopy and artificial intelligence technology as a Multi Cancer Early Detection (MCED) Platform.

Image credit | DXcover

Related Articles

Laboratory errors in transfusion: Learning for the laboratory

Anne Lockhart, IBMS representative, and Victoria Tuckley from the Serious Hazards of Transfusion (SHOT) scheme explain their latest annual report.


CRISPR treatment for blood diseases

A collaborative team of researchers has presented preliminary data showing that a CRISPR-based gene-editing therapy for inherited blood disorders is safe and effective.

A new screening paradigm

Dr Eric Klein explains why a new blood test that can detect more than 50 types of cancer is set to have a huge clinical impact.

First blood biomarker for myocarditis

Scientists have identified the first blood biomarker for myocarditis – a cardiac disease that is often misdiagnosed as myocardial infarction.